Clinical Trial Update: Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) [Phase 3]

View source ↗

Summary

Phase 3 HERCULES study of the BTK inhibitor Tolebrutinib (SAR442168) in non-relapsing secondary progressive multiple sclerosis has completed and results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• Tolebrutinib (SAR442168) (Tolebrutinib)

Snippet

Sponsor: Sanofi | Conditions: Non-relapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-06-18